Literature DB >> 26722544

The investigation of glucose metabolism and insulin secretion in subjects of chronic hepatitis B with cirrhosis.

Chun-Hui Guo1, Ting-Ting Sun1, Xi-Ding Weng1, Jian-Chun Zhang1, Jian-Xin Chen1, Guo-Jiong Deng1.   

Abstract

AIMS: To investigate the situations of abnormal glucose metabolism and dysfunction of pancreatic islet beta cells in subjects of chronic hepatitis B (CHB) with cirrhosis.
METHODS: 106 hepatitis B virus (HBV) positive subjects with liver cirrhosis as well as with different grade of Child-Pugh and 37 healthy subjects were included in this study. The oral glucose tolerance test (OGTT), C-peptide and insulin release test were detected. Plasma glucose and insulin levels were analyzed periodically for 2 h after oral glucose loading.
RESULTS: There was no significant difference in the level of fasting plasma glucose and C-peptide between cirrhosis group and control group (P>0.05). The levels of OGTT 2 h glucose, insulin and C peptide were significantly higher in cirrhosis group than control group (P<0.01). Peak plasma glucose levels were obtained at 60 min in normal group and cirrhosis group. The peak insulin and C-peptide response occurred at 60 min in normal group, whereas it was delayed to 120 min in cirrhosis group. There was a significant difference between two groups in the pattern of plasma glucose levels at corresponding time points (P<0.05). The OGTT 2 h glucose and insulin levels were positively correlated with Child-Pugh Score (r1 = 0.389, r2 = 0.508, P<0.01).
CONCLUSION: These findings implied that there was a certain degree of insulin resistance and abnormal glucose metabolism in the patients with liver cirrhosis.

Entities:  

Keywords:  Glucose metabolism; hepatitis virus; insulin secretion; liver cirrhosis; oral glucose tolerance test

Mesh:

Substances:

Year:  2015        PMID: 26722544      PMCID: PMC4680489     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  15 in total

1.  Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection.

Authors:  Chao-Hung Hung; Jing-Houng Wang; Tsung-Hui Hu; Chien-Hung Chen; Kuo-Chin Chang; Yi-Hao Yen; Yuan-Hung Kuo; Ming-Chao Tsai; Sheng-Nan Lu; Chuan-Mo Lee
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Glucose tolerance and diabetes in chronic liver disease.

Authors:  C Megyesi; E Samols; V Marks
Journal:  Lancet       Date:  1967-11-18       Impact factor: 79.321

3.  Liver cirrhosis and diabetes mellitus.

Authors:  D Muting; D Wohlgemuth; R Dorsett
Journal:  Geriatrics       Date:  1969-01

4.  Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis.

Authors:  Y T Kruszynska; P D Home; N McIntyre
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

5.  Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus.

Authors:  S Y Kwon; S S Kim; O S Kwon; K A Kwon; M G Chung; D K Park; Y S Kim; Y S Koo; Y K Kim; D J Choi; J H Kim
Journal:  Diabet Med       Date:  2005-11       Impact factor: 4.359

6.  Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL.

Authors:  Naoki Matsumoto; Yasuji Arase; Yuya Seko; Norihiro Imai; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Mariko Kobayashi; Masahiro Kobayashi; Yoshiyuki Suzuki; Satoshi Saito; Fumitaka Suzuki; Kenji Ikeda; Hiromitsu Kumada; Kaoru Aida; Tetsuro Kobayashi
Journal:  Hepatol Res       Date:  2012-01-11       Impact factor: 4.288

7.  Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort.

Authors:  Li-Ting Chao; Chih-Feng Wu; Feng-Yu Sung; Chih-Lin Lin; Chun-Jen Liu; Chi-Jung Huang; Keh-Sung Tsai; Ming-Whei Yu
Journal:  Carcinogenesis       Date:  2011-04-03       Impact factor: 4.944

8.  Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection.

Authors:  Salvatore Petta; Calogero Cammà; Vito Di Marco; Fabio Salvatore Macaluso; Marcello Maida; Giuseppe Pizzolanti; Beatrice Belmonte; Daniela Cabibi; Rosa Di Stefano; Donatella Ferraro; Carla Guarnotta; Giovanna Venezia; Antonio Craxì
Journal:  Liver Int       Date:  2011-01-30       Impact factor: 5.828

Review 9.  Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.

Authors:  Diego Garcia-Compean; Joel Omar Jaquez-Quintana; Jose Alberto Gonzalez-Gonzalez; Hector Maldonado-Garza
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

10.  Diabetes mellitus in patients with liver cirrhosis.

Authors:  J Vidal; J P Ferrer; E Esmatjes; J M Salmeron; J M González-Clemente; R Gomis; J Rodés
Journal:  Diabetes Res Clin Pract       Date:  1994-08       Impact factor: 5.602

View more
  6 in total

Review 1.  A Different Perspective for Management of Diabetes Mellitus: Controlling Viral Liver Diseases.

Authors:  Yingying Zhao; Huichun Xing
Journal:  J Diabetes Res       Date:  2017-03-02       Impact factor: 4.011

2.  Metabolic regulations of a decoction of Hedyotis diffusa in acute liver injury of mouse models.

Authors:  Min Dai; Fenglin Wang; Zengcheng Zou; Gemin Xiao; Hongjie Chen; Hongzhi Yang
Journal:  Chin Med       Date:  2017-12-20       Impact factor: 5.455

3.  Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma.

Authors:  Pei-Song Bai; Nan Xia; Hong Sun; Ying Kong
Journal:  J Cell Mol Med       Date:  2017-05-30       Impact factor: 5.310

4.  Metabolomic Analysis Identifies Glycometabolism Pathways as Potential Targets of Qianggan Extract in Hyperglycemia Rats.

Authors:  Mingzhe Zhu; Meng Li; Wenjun Zhou; Guangbo Ge; Li Zhang; Guang Ji
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

5.  Non-Targeted UHPLC-Q-TOF/MS-Based Metabolomics Reveals a Metabolic Shift from Glucose to Glutamine in CPB Cells during ISKNV Infection Cycle.

Authors:  Xiaozhe Fu; Xixi Guo; Shiwei Wu; Qiang Lin; Lihui Liu; Hongru Liang; Yinjie Niu; Ningqiu Li
Journal:  Metabolites       Date:  2019-09-04

6.  Fasting Blood Glucose, Cholesterol, and Risk of Primary Liver Cancer: The Kailuan Study.

Authors:  Xiangming Ma; Haozhe Cui; Miaomiao Sun; Qian Liu; Xining Liu; Guangjian Li; Yaochen Wei; Qingjiang Fu; Siqing Liu; Liying Cao
Journal:  Cancer Res Treat       Date:  2021-01-19       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.